BPC-157
The tissue-healing workhorse — accelerates repair of tendons, ligaments, gut lining, and nerves via VEGF-driven angiogenesis.
Research facts
| Half-life | ~4h SubQ / ~8h oral |
|---|---|
| Route | SubQ / IM / Oral |
| Typical dose | 250–500 mcg/day |
| Frequency | Once or twice daily |
| Solvent | Bacteriostatic water |
| pH | 5.5–7.0 |
| Stability | 30 days at +4°C |
Mechanism of action
BPC-157 is a synthetic 15-amino acid pentadecapeptide derived from a protective protein found in human gastric juice (BPC). It acts primarily through upregulation of VEGF and its receptor expression, driving angiogenesis — the formation of new blood vessels — in damaged tissue. This vascular response underpins its broad healing effects across disparate tissue types.
It also modulates the nitric oxide (NO) synthase pathway, enhancing vasodilation and endothelial repair. BPC-157 activates the growth hormone receptor signalling cascade locally, accelerating fibroblast activation and improving tendon/ligament cell survival under oxidative stress. Its gut-protective effects involve upregulation of mucosal integrity genes and suppression of TNF-α and NF-κB inflammatory cascades — explaining its documented efficacy in inflammatory bowel models.
Over 150 peer-reviewed animal studies demonstrate BPC-157's comprehensive tissue-protective properties. Human pharmacokinetic data is limited: early-phase trials in IBD used oral formulations. The compound has never progressed to Phase III trials despite decades of preclinical promise, which is why it remains C-tier despite widespread use.
Documented effects (research-model)
- Accelerates tendon and ligament healing (Achilles, rotator cuff, MCL models)
- Protects and heals GI mucosal lining (IBD, NSAID damage, leaky gut)
- CNS neuroprotection and dopaminergic system support
- Angiogenesis-driven wound healing
- Bone fracture recovery acceleration
- Liver protection and hepatotoxicity reversal
- Anti-ulcer effects via mucosal prostaglandin upregulation
Research protocols
| Protocol | Dose | Frequency | Cycle | Vial |
|---|---|---|---|---|
| Standard | 250 mcg | Once daily SubQ | 8–12 weeks | 2mg / 2mL BAC water |
| Advanced | 500 mcg | Twice daily | 8 weeks | 5mg / 2mL BAC water |
Research context only. Not medical advice. Consult a qualified healthcare professional before any protocol decision.
Synergies
- TB-500 HIGH
The Wolverine Stack — BPC-157 drives localised angiogenesis and nerve repair; TB-500 provides systemic actin upregulation and cell migration. Complementary local + systemic healing. - GHK-Cu HIGH
BPC-157 builds the vascular infrastructure; GHK-Cu synthesises the collagen matrix. Angiogenesis + matrix reconstruction. - Ipamorelin MODERATE
Local tissue repair (BPC) + systemic GH pulse for amplified recovery.
Myths & misconceptions
Evidence gaps
- No completed randomised controlled trials in humans. All efficacy data is animal-derived.
- Long-term safety profile in humans is entirely unknown — no study has followed subjects beyond a few months.
- Optimal route of administration for specific injuries remains unresolved (SubQ vs. IM vs. oral).
- Interaction with oncological processes: BPC-157 upregulates VEGF, which could theoretically accelerate tumour angiogenesis. No human data exists on this risk.
Safety notes
Well-tolerated in animal models across hundreds of studies. No significant toxicity at research doses. Injection site reactions possible. VEGF upregulation — theoretical concern in individuals with active malignancy.
Biomarkers to monitor
Primary-source citations
- PMID 9100337 — Stable gastric pentadecapeptide BPC 157 in trials for IBD (PL-10) (Curr Pharm Des. 2011)
- PMID 10906069 — BPC 157 accelerates healing of transected rat Achilles tendon (J Orthop Res. 2000)
- PMID 24165960 — BPC-157 in central nervous system disorders (Curr Neuropharmacol. 2014)
Frequently asked
What is BPC-157?
BPC-157 (Body Protection Compound-157) is a research compound classified in our library as Tier C — Limited human trials; effect size uncertain.. The tissue-healing workhorse — accelerates repair of tendons, ligaments, gut lining, and nerves via VEGF-driven angiogenesis.
What is the evidence tier for BPC-157?
We classify BPC-157 as Tier C: Limited human trials; effect size uncertain. See our full peptide evidence tiers explainer for how we assign S/A/B/C/D.
What is the research dose of BPC-157?
For BPC-157, typical research dose is 250–500 mcg/day, route is SubQ / IM / Oral, half-life is ~4h SubQ / ~8h oral. Protocols vary by research goal — see the protocols section on this page for standard and advanced dosing schedules. Research use only, not medical advice.
What does BPC-157 stack well with?
BPC-157 stacks well with TB-500. The Wolverine Stack — BPC-157 drives localised angiogenesis and nerve repair; TB-500 provides systemic actin upregulation and cell migration. Complementary local + systemic healing.
Is BPC-157 safe?
Well-tolerated in animal models across hundreds of studies. No significant toxicity at research doses. Research context only — no compound on this site is approved for human therapeutic use unless explicitly noted.